{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059329","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.101127+00:00","generated_at":"2026-06-02T07:12:54.193470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Structure Therapeutics reports Q1 net loss $26M; GSBR-1290 Phase 2a obesity data due June 2024","bullets":["Net loss $26.0M in Q1 2024 vs $18.0M in Q1 2023; cash $436.4M funds projected operations through at least 2026.","Topline GSBR-1290 Phase 2a obesity 12-week data for 40 participants expected June 2024; Phase 2b obesity study to start Q4 2024.","R&D expenses $20.7M (+58% YoY) driven by GLP-1R franchise; G&A expenses $11.3M (+74% YoY) from public company infrastructure.","Plan to initiate first-in-human Phase 1 trial of LTSE-2578 (oral LPA1R antagonist for IPF) in June 2024.","Amylin candidate selection expected Q4 2024; GIPR candidate selection H1 2025; ANPA-0073 (APJR) Phase 1 completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059329","json":"https://secwatch.observer/filing/0001104659-24-059329.json","markdown":"https://secwatch.observer/filing/0001104659-24-059329.md","text":"https://secwatch.observer/filing/0001104659-24-059329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/0001104659-24-059329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/tm2413721d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:12:54.193470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd4e8fa2b81af8272d671ffa45dcbdd77521c31f","claim":"Structure Therapeutics Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 totaled $26.0 million.","evidence_excerpt":"Structure Therapeutics Inc. (the \"Company\") issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/0001104659-24-059329-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter of 2024 totaled $26.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}